MedPath
HSA Approval

Pandemic Influenza Vaccine H5N1 Baxter Suspension for Injection

SIN14278P

Pandemic Influenza Vaccine H5N1 Baxter Suspension for Injection

Pandemic Influenza Vaccine H5N1 Baxter Suspension for Injection

December 19, 2012

PHARMENG TECHNOLOGY PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMENG TECHNOLOGY PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SUSPENSION

INTRAMUSCULAR

Medical Information

J07BB01

influenza, inactivated, whole virus

Manufacturer Information

PHARMENG TECHNOLOGY PTE. LTD.

Baxter AG

Active Ingredients

A/Vietnam/1203/2004 (H5N1)

7.5µg haemagglutinin per 0.5ml

Documents

Package Inserts

Baxter H5N1 vaccine PI.pdf

Approved: December 19, 2012

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Pandemic Influenza Vaccine H5N1 Baxter Suspension for Injection - HSA Approval | MedPath